Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19223753rdf:typepubmed:Citationlld:pubmed
pubmed-article:19223753lifeskim:mentionsumls-concept:C0001792lld:lifeskim
pubmed-article:19223753lifeskim:mentionsumls-concept:C0279628lld:lifeskim
pubmed-article:19223753lifeskim:mentionsumls-concept:C0016360lld:lifeskim
pubmed-article:19223753lifeskim:mentionsumls-concept:C0851346lld:lifeskim
pubmed-article:19223753lifeskim:mentionsumls-concept:C0444889lld:lifeskim
pubmed-article:19223753lifeskim:mentionsumls-concept:C0205195lld:lifeskim
pubmed-article:19223753lifeskim:mentionsumls-concept:C1533148lld:lifeskim
pubmed-article:19223753lifeskim:mentionsumls-concept:C0332173lld:lifeskim
pubmed-article:19223753lifeskim:mentionsumls-concept:C0332293lld:lifeskim
pubmed-article:19223753lifeskim:mentionsumls-concept:C0093999lld:lifeskim
pubmed-article:19223753pubmed:issue2lld:pubmed
pubmed-article:19223753pubmed:dateCreated2009-2-19lld:pubmed
pubmed-article:19223753pubmed:abstractTextWe report an elderly patient with esophageal adenocarcinoma in whom a complete response (CR) was obtained by chemoradiotherapy using daily low-dose nedaplatin (CDGP) and continuous infusion of 5-FU. A 86-year-old man who had non-tuberculous mycobacterial infection was admitted for dysphagia, and diagnosed with Stage II A (T2N0M0) esophageal adenocarcinoma of the lower esophagus according to the TNM classification (sixth edition) of the International Union against Cancer (UICC). Chemoradiotherapy using daily low-dose CDGP and continuous infusion of 5- FU was performed, and thereafter one cycle of chemotherapy using CDGP and 5-FU was added. As the side effects of treatment, grade 3 leucopenia was observed while he was receiving chemoradiotherapy. A year later, he presented with grade 2 pericardial and pleural effusion and recovered with conservative treatment. CR was obtained and has been continued for two years. Definitive chemoradiotherapy using daily low-dose CDGP and continuous infusion of 5-FU is an effective choice for elderly and high-risk patients with esophageal adenocarcinoma.lld:pubmed
pubmed-article:19223753pubmed:languagejpnlld:pubmed
pubmed-article:19223753pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19223753pubmed:citationSubsetIMlld:pubmed
pubmed-article:19223753pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19223753pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19223753pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19223753pubmed:statusMEDLINElld:pubmed
pubmed-article:19223753pubmed:monthFeblld:pubmed
pubmed-article:19223753pubmed:issn0385-0684lld:pubmed
pubmed-article:19223753pubmed:authorpubmed-author:IkumaMutsuhir...lld:pubmed
pubmed-article:19223753pubmed:authorpubmed-author:FurutaTakahis...lld:pubmed
pubmed-article:19223753pubmed:authorpubmed-author:YoshidaKen-ic...lld:pubmed
pubmed-article:19223753pubmed:authorpubmed-author:SugimotoKenKlld:pubmed
pubmed-article:19223753pubmed:authorpubmed-author:KodairaChiseClld:pubmed
pubmed-article:19223753pubmed:authorpubmed-author:YamadaTakanor...lld:pubmed
pubmed-article:19223753pubmed:authorpubmed-author:IwaizumiMoriy...lld:pubmed
pubmed-article:19223753pubmed:authorpubmed-author:FutamiHajimeHlld:pubmed
pubmed-article:19223753pubmed:authorpubmed-author:MuramatsuAkik...lld:pubmed
pubmed-article:19223753pubmed:authorpubmed-author:OsawaSatoshiSlld:pubmed
pubmed-article:19223753pubmed:authorpubmed-author:HamayaYasushi...lld:pubmed
pubmed-article:19223753pubmed:authorpubmed-author:TakagakiKosuk...lld:pubmed
pubmed-article:19223753pubmed:authorpubmed-author:NishinoMasafu...lld:pubmed
pubmed-article:19223753pubmed:issnTypePrintlld:pubmed
pubmed-article:19223753pubmed:volume36lld:pubmed
pubmed-article:19223753pubmed:ownerNLMlld:pubmed
pubmed-article:19223753pubmed:authorsCompleteYlld:pubmed
pubmed-article:19223753pubmed:pagination309-12lld:pubmed
pubmed-article:19223753pubmed:meshHeadingpubmed-meshheading:19223753...lld:pubmed
pubmed-article:19223753pubmed:meshHeadingpubmed-meshheading:19223753...lld:pubmed
pubmed-article:19223753pubmed:meshHeadingpubmed-meshheading:19223753...lld:pubmed
pubmed-article:19223753pubmed:meshHeadingpubmed-meshheading:19223753...lld:pubmed
pubmed-article:19223753pubmed:meshHeadingpubmed-meshheading:19223753...lld:pubmed
pubmed-article:19223753pubmed:meshHeadingpubmed-meshheading:19223753...lld:pubmed
pubmed-article:19223753pubmed:meshHeadingpubmed-meshheading:19223753...lld:pubmed
pubmed-article:19223753pubmed:meshHeadingpubmed-meshheading:19223753...lld:pubmed
pubmed-article:19223753pubmed:meshHeadingpubmed-meshheading:19223753...lld:pubmed
pubmed-article:19223753pubmed:meshHeadingpubmed-meshheading:19223753...lld:pubmed
pubmed-article:19223753pubmed:meshHeadingpubmed-meshheading:19223753...lld:pubmed
pubmed-article:19223753pubmed:year2009lld:pubmed
pubmed-article:19223753pubmed:articleTitle[A case of elderly esophageal adenocarcinoma successfully treated with daily low-dose nedaplatin (CDGP) and continuous infusion of 5-FU combined with radiation].lld:pubmed
pubmed-article:19223753pubmed:affiliationFirst Dept. of Medicine, Hamamatsu University School of Medicine.lld:pubmed
pubmed-article:19223753pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:19223753pubmed:publicationTypeEnglish Abstractlld:pubmed
pubmed-article:19223753pubmed:publicationTypeCase Reportslld:pubmed